Anti-Hepatitis B Virus Surface Antigen (Ad/Ay) antibody (ab9193)
Key features and details
- Horse polyclonal to Hepatitis B Virus Surface Antigen (Ad/Ay)
- Suitable for: ELISA
- Reacts with: Hepatitis B virus
- Isotype: IgG
Overview
-
Product name
Anti-Hepatitis B Virus Surface Antigen (Ad/Ay) antibody
See all Hepatitis B Virus Surface Antigen (Ad/Ay) primary antibodies -
Description
Horse polyclonal to Hepatitis B Virus Surface Antigen (Ad/Ay) -
Host species
Horse -
Specificity
This antibody is specific for Hepatitis B surface antigen -
Tested applications
Suitable for: ELISAmore details -
Species reactivity
Reacts with: Hepatitis B virus -
Immunogen
Immunization of horses with highly purified Ad/Ay antigen.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.20
Constituents: 0.0268% PBS, 0.87% Sodium chloride -
Concentration information loading...
-
Purity
Affinity purified -
Purification notes
This antibody was immunoaffinity purified from non-recombinant hepatitis antigens. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Conjugation kits
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab9193 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
ELISA |
Use at an assay dependent concentration.
|
Notes |
---|
ELISA
Use at an assay dependent concentration. |
Target
-
Relevance
Hepatitis B Virus (HBV) infection induces a disease state characterised by liver damage, inflammation and viral persistence. Infection also increases the risk of hepatocellular carcinoma. HBV belongs to the Hepadnaviridae family of viruses. Its genome consists of partially double stranded circular DNA. The DNA is enclosed in a nucleocapsid, or core antigen (HBcAg), which is surrounded by a spherical envelope (surface antigen or HBsAg). The core antigen shares its sequences with the e antigen (HBeAg) but no cross reactivity between the two proteins has been observed. The HBV genome also encodes a DNA polymerase that also acts as a reverse transcriptase. Hepatitis B infection is normally diagnosed from serological tests that detect HBsAg but as the disease progresses this antigen may no longer be present in the blood and tests for HBcAg are used. If HBsAg can be detected in the blood for longer than six months, chronic hepatitis B is diagnosed. The antigenic determinant of the protein moiety of the HBsAg determines specific characteristics of different serotypes and provides the basis of immunodetection. HBsAg has antigenic heterogeneity, specifically, two pairs of sub specific determinants, d/y and w/r allow the following combinations: adw, ayw, adr, ayr. -
Cellular localization
Virion membrane -
Database links
- Entrez Gene: 2828293 Hepatitis B virus
- Entrez Gene: 944569 Hepatitis B virus
- SwissProt: P03138 Hepatitis B virus
- SwissProt: P03140 Hepatitis B virus
- SwissProt: P03141 Hepatitis B virus
- SwissProt: Q81157 Hepatitis B virus
- SwissProt: Q81158 Hepatitis B virus
- SwissProt: Q81159 Hepatitis B virus
see all -
Alternative names
- HBsAg antibody
- HBV major surface antigen antibody
- HBV surface antigen antibody
see all
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (28)
ab9193 has been referenced in 28 publications.
- Zhang J et al. Interleukin-17A pretreatment attenuates the anti-hepatitis B virus efficacy of interferon-alpha by reducing activation of the interferon-stimulated gene factor 3 transcriptional complex in hepatitis B virus-expressing HepG2 cells. Virol J 19:28 (2022). PubMed: 35144643
- Liu T et al. In vitro investigation of HBV clinical isolates from Chinese patients reveals that genotype C isolates possess higher infectivity than genotype B isolates. Virol Sin 37:398-407 (2022). PubMed: 35314401
- Pantazica AM et al. Efficient cellular and humoral immune response and production of virus-neutralizing antibodies by the Hepatitis B Virus S/preS116-42 antigen. Front Immunol 13:941243 (2022). PubMed: 35935966
- Zhang J et al. ATP1B3 Restricts Hepatitis B Virus Replication Via Reducing the Expression of the Envelope Proteins. Virol Sin N/A:N/A (2021). PubMed: 33534085
- Dou Y et al. The CAG promoter maintains high-level transgene expression in HEK293 cells. FEBS Open Bio 11:95-104 (2021). PubMed: 33155423